Filing Details
- Accession Number:
- 0000950170-24-094800
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-08-09 16:30:11
- Reporting Period:
- 2024-08-07
- Accepted Time:
- 2024-08-09 16:30:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1253689 | Glycomimetics Inc | GLYC | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1053890 | Raymond Debbane | 750 Lexington Avenue 30Th Floor New York NY 10022 | No | No | No | No | |
| 1340096 | Invus Public Equities Advisors, Llc | 750 Lexington Avenue 30Th Floor New York NY 10022 | No | No | No | No | |
| 1340097 | Invus Public Equities, L.p. | 750 Lexington Avenue 30Th Floor New York NY 10022 | No | No | No | No | |
| 2005245 | Siren, L.l.c. | C/O The Invus Group, Llc 750 Lexington Avenue 30Th Floor New York NY 10022 | No | No | No | No | |
| 2005369 | Invus Global Management, Llc | 750 Lexington Avenue 30Th Floor New York NY 10022 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-08-07 | 61,488 | $0.18 | 6,578,438 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-08-08 | 260,873 | $0.19 | 6,317,565 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
- Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
